Table 3.
Characteristics per CMS in the FFPE-RNA application cohort classified with the CMSFFPE classifier.
| CMS1, n = 4 (%) | CMS2, n = 58 (%) | CMS3, n = 10 (%) | CMS4, n = 32 (%) | P-valuea | |
|---|---|---|---|---|---|
| Age (years) median (IQR) | 48.5 (45.0–68.5) | 59.0 (52.0–68.0) | 58.0 (52.3–63.0) | 61.0 (50.0–69.0) | 0.573 |
| Sex | 0.877 | ||||
| Female | 1 (25.0) | 18 (31.0) | 3 (30.0) | 7 (21.9) | |
| Male | 3 (75.0) | 40 (69.0) | 7 (70.0) | 25 (78.1) | |
| WHO performance status | 0.669 | ||||
| 0 | 3 (75.0) | 25 (43.1) | 8 (80.0) | 14 (43.8) | |
| 1 | 1 (25.0) | 9 (15.5) | 1 (10.0) | 8 (25.0) | |
| 2 | — | 4 (6.9) | — | 2 (6.3) | |
| 3 | — | 1 (1.7) | — | — | |
| 4 | — | — | — | — | |
| Unknown | — | 19 (32.8) | 1 (10.0) | 8 (25.0) | |
| Sidedness | 0.087 | ||||
| Left | 1 (25.0) | 48 (82.8) | 9 (90.0) | 28 (87.5) | |
| Right | 3 (75.0) | 8 (13.8) | 1 (10.0) | 4 (12.5) | |
| Unknown | — | 2 (3.4) | - | — | |
| MMR status | 0.041 | ||||
| MSI | 1 (25.0) | — | — | 1 (3.1) | |
| MSS | 3 (75.0) | 58 (100) | 10 (100) | 31 (96.9) | |
| Metastases | 0.590 | ||||
| Synchronous | 1 (25.0) | 51 (87.9) | 9 (90.0) | 27 (84.4) | |
| Metachronous | 3 (75.0) | 6 (10.3) | 1 (10.0) | 5 (15.6) | |
| Unknown | — | 1 (1.7) | — | — | |
| Location of metastases | |||||
| Liver | 3 (75.0) | 56 (96.6) | 7 (70) | 26 (81.3) | 0.010 |
| Lung | 2 (50.0) | 25 (43.1) | 2 (20.0) | 9 (28.1) | 0.323 |
| Peritoneum | 2 (50.0) | 12 (20.7) | 1 (10.0) | 11 (34.4) | 0.194 |
| Lymph nodes | 3 (75.0) | 23 (39.7) | 3 (30.0) | 9 (28.1) | 0.274 |
| Bones | — | 7 (12.1) | 2 (20.0) | 2 (6.3) | 0.546 |
| Other | — | 11 (19.0) | 3 (30.0) | 4 (12.5) | 0.529 |
| Surgery of primary | 0.017 | ||||
| Yes | 4 (100) | 36 (62.1) | 3 (30.0) | 25 (78.1) | |
| No | — | 22 (37.9) | 7 (70.0) | 7 (21.9) | |
| Chemotherapy | 0.017 | ||||
| Yes | 4 (100) | 36 (62.1) | 3 (30.0) | 25 (78.1) | |
| No | — | 22 (37.9) | 7 (70.0) | 7 (21.9) | |
| Number of treatment lines | 0.419 | ||||
| None | — | — | — | 2 (6.3) | |
| 1 | 3 (75.0) | 22 (37.9) | 4 (40.0) | 13 (40.6) | |
| 2 | — | 18 (31.0) | 4 (40.0) | 7 (21.9) | |
| 3 | — | 8 (13.8) | — | 7 (21.9) | |
| >3 | 1 (25.0) | 10 (17.2) | 2 (20.0) | 3 (9.4) | |
| Anti-EGFR treated | 0.561 | ||||
| Yes | 1 (25.0) | 35 (60.3) | 7 (70.0) | 19 (59.4) | |
| No | 3 (75.0) | 23 (39.7) | 3 (30.0) | 13 (40.6) |
n, number of patients; IQR, interquartile range; WHO, World Health Organization; MMR, mismatch repair; MSI, microsatellite unstable; MSS, microsatellite stable; EGFR, endothelial growth factor receptor.
a
P-values are calculated with the Fisher-Freeman Halton Exact test for categorical variables and the Kruskal-Wallis test for median age comparison between groups.